Revance Therapeutics to Release Fourth Quarter and Full Year 2013 Financial Results and Host Conference Call on Wednesday, March

Revance Therapeutics to Release Fourth Quarter and Full Year 2013 Financial
Results and Host Conference Call on Wednesday, March 26, 2014

NEWARK, Calif., March 12, 2014 (GLOBE NEWSWIRE) -- Revance Therapeutics, Inc.
(Nasdaq:RVNC), a specialty biopharmaceutical company which develops botulinum
toxin products for use in aesthetic and therapeutic indications, today
announced that the company will release fourth quarter and full year 2013
financial results on Wednesday, March 26, 2014 after the close of market.
Revance will host a conference call and a live Internet webcast at 1:30pm
PT/4:30pm ET on the same day to discuss the results and provide a business

Individuals interested in listening to the conference call may do so by
dialing (855) 453-3827 for domestic callers, or (484) 756-4301 for
international callers, or from the webcast link in the investor relations
section of the Company's website at: Participants should
allow approximately five to 10 minutes prior to the call's start time to visit
the site and to download any streaming media software needed to listen to the
Internet webcast. The webcast will be available in the Investor Relations
section on the Company's website for 30 days following the completion of the

About Revance Therapeutics, Inc.

Revance is a specialty biopharmaceutical company focused on the development,
manufacturing and commercialization of novel botulinum toxin products for
multiple aesthetic and therapeutic applications. The Company is leveraging its
proprietary portfolio of botulinum toxin compounds combined with its patented
TransMTSĀ® peptide delivery system to address unmet needs in the large and
growing aesthetic and therapeutic botulinum toxin market. Revance's
proprietary TranMTS technology enables transcutaneous delivery of botulinum
toxin A, eliminating the need for injections. The Company's lead product
candidate, RT001, is a topical formulation of botulinum toxin type A, which
has the potential to be the first commercially-available non-injectable dose
form. RT001 is being evaluated in a broad clinical program that includes
aesthetic indications such as crow's feet lines (wrinkles around the eyes) and
therapeutic indications such as hyperhidrosis (excessive sweating) and
migraine headache. Revance also has a second product candidate, RT002, a novel
injectable formulation of botulinum toxin type A designed to be more targeted
and longer lasting than currently available botulinum toxin injectable

CONTACT: Westwicke Partners
         Ana Petrovic
         (415) 513-1281
Press spacebar to pause and continue. Press esc to stop.